Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mu Sun

Showing results (331-340 of 338) with videos related to

Pageof 34
Sort By:
You have reached the last page of results.This site can display upto 338 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2023
Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With <i>EGFR</i>- or <i>ALK</i>-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)Sehhoon Park, Tae Min Kim, Ji-Youn Han, et al.
International Journal of Oncology|November 20, 2013
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart reviewWilliam K Oh, David McDermott, Camillo Porta, et al.
Oncotarget|October 14, 2015
Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinomaHyo Song Kim, Sung-Moo Kim, Hyunki Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2022
Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung CancerSehhoon Park, Chan-Young Ock, Hyojin Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 27, 2021
A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase InhibitorsByoung Chul Cho, Ji-Youn Han, Sang-We Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 27, 2014
Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neckHan Sang Kim, Hyeong Ju Kwon, Inkyung Jung, et al.
Oncotarget|September 24, 2015
The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysisSeung Tae Kim, Jeeyun Lee, Mineui Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2013
Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patientsYoungwook Kim, Peter S Hammerman, Jaegil Kim, et al.
Pageof 34

Showing results (331-340 of 338) with videos related to

Sort By:
Pageof 34
You have reached the last page of results.This site can display upto 338 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2023
Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With <i>EGFR</i>- or <i>ALK</i>-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)Sehhoon Park, Tae Min Kim, Ji-Youn Han, et al.
International Journal of Oncology|November 20, 2013
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart reviewWilliam K Oh, David McDermott, Camillo Porta, et al.
Oncotarget|October 14, 2015
Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinomaHyo Song Kim, Sung-Moo Kim, Hyunki Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2022
Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung CancerSehhoon Park, Chan-Young Ock, Hyojin Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 27, 2021
A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase InhibitorsByoung Chul Cho, Ji-Youn Han, Sang-We Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 27, 2014
Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neckHan Sang Kim, Hyeong Ju Kwon, Inkyung Jung, et al.
Oncotarget|September 24, 2015
The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysisSeung Tae Kim, Jeeyun Lee, Mineui Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2013
Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patientsYoungwook Kim, Peter S Hammerman, Jaegil Kim, et al.
Pageof 34